InMed Pharmaceuticals (INM)
NASDAQ:INM
INM Stock Chart & Stats
$1.12
-$0.34(-7.10%)
At close: 4:00 PM EST
$1.12
-$0.34(-7.10%)
Day’s Range― - ―
52-Week Range$0.65 - $7.98
Previous CloseN/A
Volume49.03K
Average Volume (3M)113.41K
Market Cap
$1.99M
Enterprise Value-$7.58M
Total Cash (Recent Filing)$9.60M
Total Debt (Recent Filing)$730.14K
Price to Earnings (P/E)―
Beta3.37
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding2,919,186
10 Day Avg. Volume156,716
30 Day Avg. Volume113,414
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.64
P/FCF Ratio-0.41
Enterprise Value/Market Cap-3.81
Enterprise Value/Revenue-1.44
Enterprise Value/Gross Profit-5.42
Enterprise Value/Ebitda0.87
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline Progress (INM-901)Robust preclinical translation into human-relevant organoid models strengthens the scientific rationale for INM-901. The dose-dependent biomarker reductions and alignment with prior in vivo results materially de-risk first-in-human readiness and support planned pre-IND engagement and a targeted Phase 1 in 2027.
Revenue And Gross Margin TrendSustained top-line growth and improving gross margins indicate better product or manufacturing economics and growing commercial traction pre-exit. These trends suggest the company can scale revenue lines and improve unit profitability, which supports longer-term operational resilience as R&D programs advance.
Low Leverage / Positive EquityA conservative balance sheet with minimal debt lowers solvency risk and interest burden, giving management flexibility to fund IND-enabling work via equity financings or collaborations. Positive equity cushions losses and reduces risk of near-term creditor-driven constraints common in clinical-stage biotechs.
Bears Say
Persistent Cash BurnOngoing, sizable negative operating and free cash flow creates structural liquidity pressure, requiring repeat capital raises or asset sales. Sustained burn increases financing risk, constrains R&D pacing and forces prioritization decisions that could delay IND timelines or shrink program scope over the medium term.
Reliance On External FinancingDependence on capital markets and equity issuance exposes the company to dilution risk and market-conditional funding gaps. Without commercial product revenues, future development pace and milestones hinge on successful financings or partnership deals, increasing execution risk across 2-6 month horizons.
Exit Of BayMedica Reduces Commercial RevenueWinding down BayMedica removes a commercialization arm and a modest revenue stream, triggers transition costs, and was driven by regulatory headwinds. This structural shift narrows near-term non-dilutive cash sources and intensifies reliance on external funding to progress clinical programs.
InMed Pharmaceuticals News
INM FAQ
What was InMed Pharmaceuticals’s price range in the past 12 months?
InMed Pharmaceuticals lowest stock price was $0.65 and its highest was $7.98 in the past 12 months.
What is InMed Pharmaceuticals’s market cap?
InMed Pharmaceuticals’s market cap is $1.99M.
When is InMed Pharmaceuticals’s upcoming earnings report date?
InMed Pharmaceuticals’s upcoming earnings report date is May 18, 2026 which is in 52 days.
How were InMed Pharmaceuticals’s earnings last quarter?
InMed Pharmaceuticals released its earnings results on Feb 11, 2026. The company reported -$0.513 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.513.
Is InMed Pharmaceuticals overvalued?
According to Wall Street analysts InMed Pharmaceuticals’s price is currently Overvalued.
Does InMed Pharmaceuticals pay dividends?
InMed Pharmaceuticals does not currently pay dividends.
What is InMed Pharmaceuticals’s EPS estimate?
InMed Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InMed Pharmaceuticals have?
InMed Pharmaceuticals has 2,919,186 shares outstanding.
What happened to InMed Pharmaceuticals’s price movement after its last earnings report?
InMed Pharmaceuticals reported an EPS of -$0.513 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -10.101%.
Which hedge fund is a major shareholder of InMed Pharmaceuticals?
Currently, no hedge funds are holding shares in INM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InMed Pharmaceuticals
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Technical Analysis
Alaunos Therapeutics
―
―
Xenetic Biosciences
―
Ensysce Biosciences
―
Pasithea Therapeutics Corp
―
Ownership Overview
13.25%
Insiders
6.91% Other Institutional Investors
79.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---